A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
about
The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic InfectionsCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsMicafungin: an evidence-based review of its place in therapyComparison of echinocandin antifungalsOpportunistic infections in HIV disease.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerOropharyngeal candidiasis in the era of antiretroviral therapyAccumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.Micafungin: a sulfated echinocandin.Echinocandins: the newest class of antifungals.Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patientsClinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisGlobal surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisFrequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTsAntimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literatureMicafungin: pharmacology, experimental therapeutics and clinical applications.Micafungin: the US perspective.New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients.Management of invasive fungal infections in neutropenic patients.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis.Developments in the treatment of candidiasis: more choices and new challenges.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Micafungin: a new echinocandin antifungal.The echinocandins.The use of caspofungin in HIV-infected individuals.Anidulafungin in the treatment of invasive fungal infections.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Micafungin activity against Candida albicans with diverse azole resistance phenotypes.A comparative evaluation of properties and clinical efficacy of the echinocandins.Clinical pharmacology of antifungal agents in pediatric patients.Micafungin for the prophylaxis and treatment of Candida infections.Current options in antifungal pharmacotherapy.
P2860
Q26751038-4E307C3C-5474-4E82-BB9E-4A5C57C0C17CQ26863344-06ABD6A7-B818-4D1B-A8B5-15CBA499795EQ27014780-6CF06B4D-8D0B-474E-B3B5-13E49426816FQ28273738-54DBDB39-2BA6-40C4-8B9F-AB9EF263C963Q30391927-411D9A40-FBC6-45F7-A911-670F6D4C48BDQ33650105-9203D013-A03D-4E89-9B94-C24CD4A5D703Q33746435-8AF66935-65F6-450D-B8F6-DEC6A30D3BB6Q33816237-D9C89F33-844C-478E-93BD-F31D9218E9E9Q34015567-3DD85DE0-0F9F-4B05-8CE2-27029824B216Q34019188-8D9F0916-FA96-4AC9-AFE6-80318866160CQ34045450-C647331A-3039-4BB4-B128-43F78089F75CQ34505582-ABC34A7D-8F14-4A04-A504-C7F656D8A38BQ35026516-B610D0B4-5F65-48B4-815F-AB4D08BC6E50Q35073614-8B9CA583-56F5-4927-A08E-5867FA461E2DQ35076974-C0BE986A-3DCC-464B-978B-C1D9E689AEB6Q35097956-251469FD-ECE3-48D4-99F2-212B93BC8559Q35515892-69687391-37E2-48C1-B336-9E5A19F35C98Q35557331-A5825015-FEBA-4A7D-A670-551933CA41EFQ35959484-A533BF8A-AC35-42C4-AA41-21BC7544B331Q36120798-9DDA2AC3-FCE6-466B-88E4-A92237CFA670Q36140652-A5E2DDBC-F1BA-4EE8-AF59-06726071F1FCQ36222041-0F9D1170-18D9-414E-BAF8-D73EC171F511Q36270118-15BBD7E0-542F-433D-9C58-ADAB0A57182EQ36441524-8B4D6F9D-C80B-4D12-BF2C-C24B8D78DB3AQ36458402-96F45B14-AF5F-4502-A088-5834B5ED01ABQ36505508-D0FC35D2-A733-4156-B444-EE7EDB325EA0Q36597431-EE854180-45EE-4706-AF69-F0DE1A0670BAQ36601954-1B94F018-E491-4473-B9A7-98FC18E1D2B5Q36623050-DFC98F13-A7BE-4B70-AA57-0E7170F63366Q36626518-FCA52514-0802-47AC-9739-A0EDE4BE3D6EQ36693843-E2DF1F8F-ED16-45E6-B843-4831D81132C4Q36742397-2DC3722A-4DCF-42AE-9A40-724B1E0E1A6EQ36821383-4BBDB18B-D0E3-4319-88AB-7F645F305F6CQ36822941-FC262EBA-FB38-4BD0-A8D9-DF913E563A77Q36828156-4798EB73-90D9-4FBB-8782-9E29DCB8C814Q36867925-4D3BC653-091D-4902-B4A9-1DC79F2D5FBFQ36895839-F883F2B3-A1EE-4F89-9E8A-8B50D91EFAA8Q36968140-A831D243-CB8F-4BAF-9F01-C5E3C8C893EDQ37124868-B678F5F3-9ED9-46C9-9872-DFF9B787E8E6Q37151326-E900C9F5-C38B-43FF-8396-1451FB26A30A
P2860
A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A randomized, double-blind, pa ...... asis in HIV-positive patients.
@en
A randomized, double-blind, pa ...... asis in HIV-positive patients.
@nl
type
label
A randomized, double-blind, pa ...... asis in HIV-positive patients.
@en
A randomized, double-blind, pa ...... asis in HIV-positive patients.
@nl
prefLabel
A randomized, double-blind, pa ...... asis in HIV-positive patients.
@en
A randomized, double-blind, pa ...... asis in HIV-positive patients.
@nl
P2093
P2860
P356
P1476
A randomized, double-blind, pa ...... asis in HIV-positive patients.
@en
P2093
Della Negra M
Diekmann-Berndt H
Llanos-Cuentas A
Suleiman J
P2860
P304
P356
10.1086/423377
P407
P577
2004-08-27T00:00:00Z